AR and urinary bladder carcinoma: We have additionally demonstrated that activation of androgen receptor (AR) is associated with resistance to CDDP therapy in bladder cancer [9], while an increasing amount of evidence indicates an important role of AR in promoting both of two distinct steps/events, urothelial tumorigenesis and tumor progression [10].